Denzil Seedial, MD
Internal Medicine · Atlantis, FLNPI 1043267909
Payments from drug & device makers
Across 469 payments — averaging $33.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- GSK$2K
- AstraZeneca$2K
- Boehringer Ingelheim$972
- Takeda Pharmaceuticals U.S.A., Inc.$710
- United Therapeutics Corporation$698
- plus $4K from 32 others
What the payments were for
- Travel & lodging$1,2928%
- Food & beverage$9,69662%
- Education$4,61930%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $5,541 |
| GSK | 108 | $1,767 |
| AstraZeneca | 63 | $1,512 |
| Boehringer Ingelheim | 40 | $972 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $710 |
| United Therapeutics Corporation | 25 | $698 |
| Inogen, Inc. | 47 | $666 |
| Actelion Pharmaceuticals US, Inc. | 15 | $588 |
| Grifols USA, LLC | 29 | $450 |
| ANI Pharmaceuticals, Inc. | 9 | $337 |
| Mallinckrodt Hospital Products Inc. | 7 | $268 |
| Regeneron Healthcare Solutions, Inc. | 9 | $244 |
| Mylan Specialty L.p. | 11 | $226 |
| Sanofi-aventis U.S. LLC | 2 | $198 |
| Verona Pharma, Inc. | 12 | $183 |
| Inspire Medical Systems, Inc. | 4 | $182 |
| Vifor Pharma, Inc. | 6 | $149 |
| Amgen | 8 | $138 |
| Insmed, Inc. | 8 | $131 |
| Sanofi | 3 | $91 |
| Genentech USA, Inc. | 2 | $80 |
| Novartis | 2 | $49 |
| Jazz Pharmaceuticals Inc. | 2 | $48 |
| Harmony Biosciences LLC | 1 | $42 |
| AbbVie | 2 | $42 |
| Johnson & Johnson | 2 | $37 |
| Lilly USA, LLC | 2 | $34 |
| Resmed Corp | 2 | $30 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Caris MPI, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $21 |
| Covis Pharma GmbH | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Apria Healthcare LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Ambu Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,405
- Inspire Upper Airway Stimulation System$138
- FASENRA$134
- AREXVY$125
- BREZTRI$125
- PURIFIED CORTROPHIN GEL$124
- NUCALA$121
How this compares
$15,608 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 372 | $362,054 |
| OfevNintedanib Esylate | 17 | $220,893 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $136,792 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 115 | $108,286 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $44,261 |
| Spiriva RespimatTiotropium Bromide | 34 | $30,082 |
| SymbicortBudesonide/Formoterol Fumarate | 66 | $25,284 |
| Arnuity ElliptaFluticasone Furoate | 50 | $15,913 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $13,590 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 280 | $8,636 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 56 | $6,583 |
| Advair DiskusFluticasone Propion/Salmeterol | 14 | $5,852 |
| Spiriva HandihalerTiotropium Bromide | 12 | $5,726 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $5,080 |
| Fluticasone Propionate HfaFluticasone Propionate | 19 | $4,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,767 | $427,309501 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $972 | $264,56566 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $710 | $136,79213 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,512 | $133,570181 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Atlantis
- Aaron CohenAtlantis$5.1M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.